Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
BACKGROUND
Our aim was to study the incidence and pattern of dyslipidemia among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) who received once-daily antiretroviral therapy (ART).


METHODS
Antiretroviral-naive HIV-infected patients with TB were recruited to a trial of once-daily nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART and treated with rifampicin-based thrice-weekly antituberculosis treatment (ATT); participants were randomized to receive didanosine (250/400 mg) and lamivudine (300 mg) with either efavirenz (600 mg) or nevirapine (400 mg) once-daily after an intensive phase of ATT. Fasting triglyceride (TG) level, total cholesterol (TC) level, low-density cholesterol (LDL-c) level and high-density cholesterol (HDL-c) level were measured at baseline and at 6 and 12 months. Lipid levels at 6 and 12 months were compared with baseline values with use of repeated measures analyses. McNemar test was used to compare the proportion of patients with lipid abnormality at baseline versus at 12 months, and χ² test was used to compare between the 2 groups.


RESULTS
Of 168 patients (79% men; mean age, 36 years; mean weight, 42 kg; median CD4+ cell count, 93 cells/mm³), 104 received efavirenz-based ART, and 64 received nevirapine-based ART. After 6 months, TC levels increased by 49 mg/dL, LDL-c levels by 30 mg/dL, and HDL-c levels increased by 18 mg/dL (P < .001 for all). At baseline and at 12 months, TC was >200 mg/dL for 1% and 26% of patients, respectively; LDL-c level was >130 mg/dL for 3% and 23%, respectively; HDL-c level was <40 mg/dL for 91% and 23%, respectively; and blood glucose level was >110 mg/dL for 14% and 13%, respectively. TC level >200 mg/dL was more common among patients who received efavirenz than among those who received nevirapine (32% vs 16%; P = .04).


CONCLUSIONS
HIV-infected patients with TB who initiate NNRTI-based ART undergo complex changes in lipid profile, highlighting the importance of screening and treating other cardiovascular disease risk factors in this population.
Tuberculosis Research Centre, Chennai, India.
Chandrasekaran
C
Padmapriyadarsini
S
S
Ramesh Kumar
Norma
N
Terrin
Gopalan
G
Narendran
Pradeep A
PA
Menon
Geetha
G
Ramachandran
Sudha
S
Subramanyan
Perumal
P
Venkatesan
Christine
C
Wanke
Soumya
S
Swaminathan
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D000995:Antitubercular Agents / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D007194:India; D008074:Lipoproteins / Q000097:blood; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D014280:Triglycerides / Q000097:blood; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy
D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D008074:Lipoproteins; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D002784:Cholesterol
HIV Med. 2005 Nov;6(6):396-402
16268821
J Acquir Immune Defic Syndr. 2007 May 1;45(1):34-42
17460470
J Infect Dis. 2004 Mar 15;189(6):1056-74
14999610
PLoS Med. 2004 Oct;1(1):e19
15526045
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):199-202
15905737
HIV Med. 2005 Mar;6(2):114-21
15807717
Curr Opin Infect Dis. 2003 Feb;16(1):19-23
12821825
Circulation. 2002 Dec 17;106(25):3143-421
12485966
Am J Hum Biol. 2008 Jul-Aug;20(4):440-5
18348170
AIDS. 2001 Dec 7;15(18):2407-14
11740191
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11
18398971
Am J Cardiol. 2005 Mar 1;95(5):586-91
15721096
Nutr Clin Pract. 2005 Dec;20(6):668-73
16306305